Abstracts tagged "Cardiovascular"

Abstract Number: 1709 • ACR Convergence 2025
Association Between Social Risk Factors and Major Adverse Cardiovascular Events Among Individuals with Rheumatic Conditions
Leah Santacroce¹, Jeong Yee², Jing Cui³, Emily Oakes¹, Hongshu Guan⁴ and Karen H. Costenbader⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Sungkyunkwan University, Suwon, MA, South Korea, ³Brigham Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital/ Harvard Medical School, Boston, ⁵Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Background/Purpose: Individuals with rheumatic conditions are at an increased risk of experiencing cardiovascular events. Social risk factors contribute to disparities in comorbidities and adverse outcomes…
Abstract Number: 2146 • ACR Convergence 2025
Impact of a Clinical Pathway on Medication Use and Outcomes in Kawasaki Disease
Jonathan Yu¹, Matthew Elias¹, Deborah Whitney¹, Sanjeev Swami¹, Kaylie Shojaie¹, Caroline Burlingame¹, Isabel Armendi¹, Malki Peskin², Melissa Lerman¹, Jerri Miller¹, Jane Lavelle¹, Brandon Ku¹ and Jon Burnham³, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Bala Cynwyd, PA, ³Children's Hospital of Philadelphia, Bryn Mawr, PA
Background/Purpose: Kawasaki disease (KD) is an acute, systemic vasculitis which can lead to coronary artery (CA) aneurysms in young children. In 2018, we developed a…
Abstract Number: 2568 • ACR Convergence 2025
Cardiovascular Risk Prediction in Systemic Lupus Erythematosus: Comparing the PREVENT and SLECRISK Models
Youngmin Kim¹, Hongshu Guan², Emily Oakes¹, Katherine Zhong³, Misti Paudel⁴, May Choi⁵, Katherine Liao¹, Brittany Weber⁶ and Karen H. Costenbader⁷, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital/ Harvard Medical School, Boston, ³Brigham and Women's Hospital, Short Hills, NJ, ⁴Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁵University of Calgary, Calgary, AB, Canada, ⁶Brigham and Women's Hospital, DEDHAM, MA, ⁷Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have increased risk for atherosclerotic cardiovascular disease (CVD) events, often underrepresented in traditional risk models. We previously developed…
Abstract Number: 0024 • ACR Convergence 2025
Biobank-scale genetic mapping identifies the shared genetic landscape of rheumatic and cardiovascular disease
Daniel Panyard¹, Daniel Li², Pik Fang Kho², Rodrigo Guarischi-Sousa³, Jiayan Zhou², Austin Hilliard⁴, Christie Bartels⁵, Philip Tsao² and Themistocles Assimes², ¹Stanford University, Sunnyvale, CA, ²Stanford University, Palo Alto, CA, ³Palo Alto Veterans Institute for Research, Palo Alto, CA, ⁴VA Palo Alto Health Care, Palo Alto, CA, ⁵University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Patients with rheumatic conditions are at increased risk for cardiovascular (CV) problems, striking on average a decade before peers and conferring substantial morbidity and…
Abstract Number: 0450 • ACR Convergence 2025
The Fibrosis-4 Index (FIB-4) Correlates with Cardiovascular Risk and Insulin Resistance in Patients with Rheumatoid Arthritis
Jose Marí Viotti-Serra¹, Elena Heras-Recuero², Juan C. Quevedo-Abeledo³, Miguel A. González-Gay⁴ and Ivan Ferraz Amaro⁵, ¹Hospital Universitario de Canarias, Tenerife, Canarias, Spain, ²Fundación Jiménez Díaz, Madrid, Madrid, Spain, ³Hospital Doctor Negrín, Las Palmas de Gran Canaria, Canarias, Spain, ⁴Department of Rheumatology and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain, and Medicine and Psychiatry Department, University of Cantabria, Santander, Spain, ⁵Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
Background/Purpose: The Fibrosis-4 index (FIB-4), a non-invasive tool for assessing liver fibrosis, has been linked to cardiovascular (CV) risk in the general population. This is…
Abstract Number: 0671 • ACR Convergence 2025
The Gut-Heart Axis in Systemic Sclerosis: Evidence from the GENISOS cohort
Francesca Romana Di Ciommo¹, Ashish Balar², Subhash Kulkarni³, Aidan K Strother², Michael Hughes⁴, Brian Skaug⁵, Maureen Mayes⁶, Shervin Assassi⁷, Ali Y Ayla² and Zsuzsanna McMahan⁸, ¹La Sapienza University of Rome, Rome, Italy, ²UTHealth Houston, Houston, TX, ³BIDMC, Boston, MA, ⁴Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, Manchester, England, United Kingdom, ⁵UTHealth Houston Division of Rheumatology, Houston, TX, ⁶UT Health Houston Division of Rheumatology, Houston, TX, ⁷Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ⁸UT Health Houston, Houston, TX
Background/Purpose: Cardiac manifestations significantly impact the prognosis of patients with systemic sclerosis (SSc), underscoring the need for early risk stratification. While gastrointestinal (GI) symptoms are…
Abstract Number: 1334 • ACR Convergence 2025
Cardiac Biomarkers and Prediction of Major Cardiovascular Events in Rheumatoid Arthritis: Results from the ESPOIR Cohort
manon lesturgie¹, Fiona Oudart¹, Anne Cauvet², Virginie Gonzalez², Bruno Fautrel³, Arnaud Constantin⁴, Nathalie Rincheval⁵, Yannick Allanore⁶ and Jérôme Avouac⁷, ¹INSERM U¹⁰¹⁶, Paris, France, ²INSERMU¹⁰¹⁶, Paris, France, ³Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France, ⁴Hôpital Pierre-Paul Riquet, CHU Purpan, Toulouse, France, ⁵Institut de Recherche Clinique EA²⁴¹⁵, Université de Montpellier, Département de Statistiques, Montpellier, France, ⁶Université Paris Cité, Paris, France, ⁷Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: Patients with rheumatoid arthritis (RA) experience premature mortality, largely due to cardiovascular (CV) disease. The increased CV risk is due to both the underlying…
Abstract Number: 1716 • ACR Convergence 2025
The frequency and impact of cardiovascular disease in systemic lupus erythematosus: a Nationwide, matched case-control study.
Jessica Fairley¹, Laura Ross¹, Elizabeth Paratz², Penelope McKelvie³, Simin Daneshvar³, Shereen Oon⁴, Dylan Hansen³, Wendy Stevens¹, Andre La Gerche² and Mandana Nikpour⁵, ¹The University of Melbourne, Melbourne, Victoria, Australia, ²St Vincent's Institute of Medical Research, Melbourne, Victoria, Australia, ³St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia, ⁴St Vincent’s Hospital Melbourne, Melbourne, Victoria, Australia, ⁵University of Sydney School of Public Health and Department of Rheumatology, Royal Prince Alfred Hospital, Sydney, Victoria, Australia
Background/Purpose: Cardiovascular disease is the leading cause of death in systemic lupus erythematosus (SLE).1 Whilst histopathology remains the gold standard for establishing the pathogenesis of…
Abstract Number: 2221 • ACR Convergence 2025
Racial Differences in Cardiovascular Events and Adverse Pregnancy Outcomes Among Pregnant Individuals With Systemic Lupus Erythematosus
Rashmi Dhital¹, Rebecca Baer² and Christina Chambers³, ¹Vanderbilt University Medical Center, Brentwood, TN, ²University of California San Diego, San Diego, CA, ³University of California, San Diego, La Jolla, CA
Background/Purpose: Pregnant individuals with systemic lupus erythematosus (SLE) face an increased risk of cardiovascular events (CVEs) as well as adverse pregnancy outcomes (APOs). While racial…
Abstract Number: 2569 • ACR Convergence 2025
Performance of the PREVENT Heart Failure General Population Risk Score in Patients with Rheumatoid Arthritis
Ilana Usiskin¹, Katherine Zhong², Ying Qi³, Lauren rusnak¹, Andrew Cagan¹, Yumeko Kawano¹, Tianrun Cai¹, Daniel Solomon⁴, Jennifer Ho⁵, Brittany Weber⁶ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Short Hills, NJ, ³Brigham and Women’s Hospital, Boston, ⁴Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, ⁵Beth Israel Deaconess Medical Center, Boston, MA, ⁶Brigham and Women's Hospital, DEDHAM, MA
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of heart failure (HF) compared to the general population, and HF with preserved ejection fraction…
Abstract Number: 0045 • ACR Convergence 2025
Genetic regulators of corticosteroid response in hepatic and adipose tissue and risk of adverse metabolic outcomes in patients with rheumatoid arthritis initiating glucocorticoids.
Thomas Riley¹, Bryant England², Austin Wheeler², Punyasha Roul³, Grant Cannon⁴, Brian Sauer⁵, Gary Kunkel⁶, Katherine Wysham⁷, Beth Wallace⁸, Andreas Reimold⁹, Gail Kerr¹⁰, Isaac Smith¹¹, John Richards¹², Iris Lee¹³, Mitchell Lazar¹, Wenxiang Hu¹⁴, Michael Levin¹⁵, Scott Damrauer¹⁵, Rui Xiao¹⁶, Tate Johnson², Ted Mikuls², Joshua Baker¹ and Michael George¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³UNMC, Omaha, NE, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁷VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁸Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁹Dallas VA Medical Center, Dallas, TX, ¹⁰Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹¹Duke University Hospital, Durham, NC, ¹²Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ¹³Washington University in St Louis, Saint Louis, MO, ¹⁴Guangzhou National Laboratory, Guangzhou, China (People's Republic), ¹⁵University of Pennsylvania / Corporal Michael J. Crescenz VAMC, Philadelphia, PA, ¹⁶Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Previous studies identified single nucleotide polymorphisms (SNPs) that affect hepatocyte and adipocyte response to glucocorticoids (GCs). We aimed to determine if these candidate SNPs…
Abstract Number: 0458 • ACR Convergence 2025
TyG-BMI Index as a Serological Biomarker for Carotid Plaque and Cardiac Function Changes in Rheumatoid Arthritis
Rebeca L. Polina-Lugo¹, Oscar Azael Garza-Flores², Fernanda M. Garcia-Garcia³, Esteban C. Garza-Gonzalez⁴, Jesus Alberto Cardenas-de la Garza⁵, Iris J. Colunga-Pedraza³, Jose R Azpiri-Lopez⁶, Dionicio A. Galarza-Delgado³, Victor M Fraga-Enriquez⁷ and Diego Azamat Salcedo Almanza⁸, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Guadalupe, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁴Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, San Nicolas de los Garza, Nuevo Leon, Mexico, ⁵Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁶Cardiology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁷Cardiology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico, ⁸Radiology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico
Background/Purpose: The Triglyceride-Glucose-BMI index (TyG-BMI) is a reliable method for detecting insulin resistance (IR), with effectiveness comparable to the gold standard. Elevated TyG-BMI levels have…
Abstract Number: 0677 • ACR Convergence 2025
Increased incidence of sudden cardiac death in systemic sclerosis: estimate & correlates.
Jessica Fairley¹, Elizabeth Paratz², Dylan Hansen³, Susanna Proudman⁴, Joanne Sahhar⁵, Gene-Siew Ngian⁶, Diane Apostolopoulos⁶, Jennifer Walker⁷, Lauren Host⁸, Wendy Stevens¹, Andre La Gerche², Mandana Nikpour⁹ and Laura Ross¹, ¹The University of Melbourne, Melbourne, Victoria, Australia, ²St Vincent's Institute of Medical Research, Melbourne, Victoria, Australia, ³St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia, ⁴The University of Adelaide, Adelaide, Victoria, Australia, ⁵Monash Health, Melbourne, Victoria, Australia, ⁶Monash University, Melbourne, Victoria, Australia, ⁷Flinders University, Adelaide, Victoria, Australia, ⁸Fiona Stanley Hospital, Perth, Victoria, Australia, ⁹University of Sydney, School of Public Health, Faculty of Medicine and Health, Sydney, New South Wales, Australia; St Vincent’s Hospital Melbourne, Department of Rheumatology, Fitzroy, Victoria, Australia, Melbourne, Victoria, Australia
Background/Purpose: The incidence of sudden cardiac death (SCD) is suspected to be increased in systemic sclerosis (SSc). However, data describing SCD incidence in SSc are…
Abstract Number: 1397 • ACR Convergence 2025
Cardiovascular And Cerebrovascular Risk In Sjögren’s Disease: Results From A Prospective Multicenter Cohort.
Olga Rusinovich¹, Zulema Plaza², Monica Fernandez Castro³, Jose Rosas Gómez de Salazar⁴, Victor Martinez-Taboada⁵, Alex Olive⁶, Raúl Menor Almagro⁷, Belén Serrano-Benavente⁸, Judit Font-Urgelles⁹, Angel Garcia-Aparicio¹⁰, Sara Manrique-Arija¹¹, Jesús Alberto Garcia Vadillo¹², Ruth Lopez-Gonzalez¹³, Javier Narváez¹⁴, Maria Beatriz Rodriguez¹⁵, Carlos Galisteo¹⁶, Jorge Juan Gonzalez Martin¹⁷, Paloma Vela Casasempere¹⁸, Cristina Bohorquez¹⁹, MARIA CELIA ERAUSQUIN ARRUABARRENA²⁰, Beatriz Paredes-Romero²¹, Leyre Riancho-Zarrabeitia²², Sheila Melchor Diaz²³, José María Pego-Reigosa²⁴, Sergi Herdia²⁵, Clara Moriano²⁶, Mª Angeles Blazquez Cañamero²⁷, Paula Estrada-Alarcón²⁸, Enrique Judez²⁹, Nerea Alcorta-Lorenzo³⁰, Consuelo Ramos Giraldez³¹, Fernando Sánchez-Alonso³² and Jose Luis Andreu³³, ¹Puerta de Hierro University Hospital, Boadilla del Monte, Spain, ²Research Unit, Spanish Society of Rheumatology, Madrid, Spain, Madrid, Spain, ³PUERTA DE HIERRO HOSPITAL, Madrid, Spain, ⁴Hospital Marina Baixa, PALMA DE MALLORCA, Spain, ⁵Facultad de Medicina. Universidad de Cantabria, Santander, Spain, ⁶Solo practice, Barcelona, Spain, ⁷Department of Rheumatology, Hospital de Jerez, Spain, Puerto De Santa María, Spain, ⁸Hospital Gregorio Marañon, Madrid, Spain, ⁹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁰Hospital Universitario de Toledo, Toledo, Spain, ¹¹Hospital Regional Universitario Málaga, Malaga, Spain, ¹²Hospital Universitario La Princesa, Madrid, Spain, ¹³Zamora Health Complex, Salamanca, Spain, ¹⁴Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁵Canarias University Hospital, La Laguna- Tenerife, Spain, ¹⁶Hospital Parc Taulí, Sabadel, Sabadel, Spain, ¹⁷HM Sanchinarro Univeristary Hospital, Madrid, Spain, ¹⁸Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ¹⁹La Paz University Hospital, Alcalá De Henares, Spain, ²⁰Dr Negrin University Hospital, Ls Palmas, Spain, ²¹Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, San Sebastian de los Reyes, Spain, ²²Rheumatology Department. Hospital Sierrallana, Torrelavega, Spain, ²³¹² de Octubre University Hospital, Madrid, Spain, ²⁴Department of Rheumatology, University Hospital of Vigo, Vigo, Spain; IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute, Vigo, Spain, ²⁵Complex Hospitalari Moisès Broggi, Barcelona, Spain, ²⁶Hospital León, LEON, Castilla y Leon, Spain, ²⁷Hospital Ramon y Cajal, Madrid, Spain, ²⁸Complex Universitari Hospital Moisès Broggi, Barcelona, Spain, ²⁹Albacete University Hospital, Albacete, Spain, ³⁰Rheumatology Department, Donostia University Hospital., San Sebastian, Spain, ³¹Hospital Universitario Virgen de Valme, Servicio de Reumatología, Seville, Spain, ³²Sociedad Española de Reumatología, Madrid, Spain, ³³Hospital Universitario Puerta de Hierro, Majadahonda, Spain
Background/Purpose: To evaluate the incidence of cardiovascular and cerebrovascular events (CVEs) in patients with Sjögren’s Disease (SjD), focusing on major adverse cardiovascular events (MACE), defined…
Abstract Number: 1743 • ACR Convergence 2025
Comparative assessment of cardiovascular risk and its predictors in a large cohort of young adults with juvenile systemic lupus erythematosus and juvenile dermatomyositis
Jiangning Li, Shreya Doddi, Tharuni Mailoo and Coziana Ciurtin, University College London, London, United Kingdom
Background/Purpose: Juvenile systemic lupus erythematosus (JSLE) and juvenile dermatomyositis (JDM) are associated with chronic inflammation that can accelerate atherosclerosis. There is no specific guidance regarding…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].